Multifunctional coating materials and their preparation methods and blood contact medical devices

The coating material prepared by pre-crosslinking with selenocysteine ​​and polyphenolic compounds and chemical crosslinking with quinone amine achieves long-term catalytic release of NO and sustained release of bivalirudin on the surface of blood contact medical devices, solving the problem of single function in the existing technology and possessing multifunctional biocompatibility and safety.

CN117427228BActive Publication Date: 2026-11-10DONGGUAN PEOPLES HOSPITAL
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202311394505.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-25
Publication Date
2026-11-10
Estimated Expiration
2043-10-25

AI Technical Summary

Technical Problem

Existing technologies struggle to achieve long-term catalytic release of endogenous NO on the surface of blood-contact medical devices, while simultaneously providing multifunctional effects such as antithrombosis, anti-inflammation, free radical scavenging, and endothelial regeneration promotion.

Method used

By pre-crosslinking selenocysteine ​​and polyphenolic compounds and then adding bivalirudin, quinone amine chemical crosslinking is carried out in an alkaline selenocysteine ​​solution to form a solid coating with a highly quinone amine network structure, thereby achieving long-term sustained release of NO and sustained release of bivalirudin.

Benefits of technology

The prepared coating material has excellent adhesion properties and long-lasting, stable NO catalytic release, endowing the device with antithrombotic, anti-inflammatory, free radical scavenging, and endothelial regeneration and repair functions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117427228B_ABST
    Figure CN117427228B_ABST
Patent Text Reader

Abstract

This invention discloses a multifunctional coating material, its preparation method, and blood contact medical devices, relating to the technical field of blood contact coating materials. Partial pre-adsorption is achieved by pre-crosslinking a substrate in a mixed solution of selenocysteine ​​and polyphenolic compounds. Then, bivalirudin is added, and an adhesive gel coating is constructed under acidic conditions based on the weak interaction between plant polyphenols and bivalirudin. Finally, the gel-coated material is placed in an alkaline solution of selenocysteine, transforming the weakly interacting gel coating into a solid coating with a highly quinone amine network structure encapsulating bivalirudin. The resulting transformed coating not only possesses excellent adhesion properties and long-lasting, stable, and controllable NO catalytic release and bivalirudin (BVLD) sustained-release properties, but also endows blood contact devices with antithrombotic, anti-inflammatory, free radical scavenging, smooth muscle cell abnormal proliferation inhibition, and rapid endothelial regeneration and repair functions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of blood contact coating materials technology, and more specifically, to multifunctional coating materials, their preparation methods, and blood contact medical devices. Background Technology

[0002] Blood contact devices are medical devices that come into direct contact with blood and are used for medical and diagnostic purposes. Due to this direct contact, these devices require good biocompatibility, low risk of thrombosis, and efficient material selection to ensure safe and effective functioning. Surface modification of blood contact devices involves a series of techniques and methods to improve the interaction between the device and blood. Contact between blood and device surfaces often triggers adverse reactions such as platelet activation, coagulation, and inflammation, potentially leading to thrombosis and tissue damage. To reduce these side effects and improve device biocompatibility, surface modification techniques are widely used.

[0003] Currently, commonly used surface modification methods include introducing coatings, modified polymers, and bioactive substances, aiming to endow device surfaces with antithrombotic, anti-inflammatory, and antibacterial properties, thereby reducing the risk of adverse reactions upon blood contact. In healthy blood vessels, NO produced by endothelial cells has functions such as regulating vasodilation, inhibiting abnormal proliferation of smooth muscle cells, and inhibiting platelet adhesion and activation. Therefore, endowing materials with sustained-release NO function through surface modification technology is very helpful in reducing side effects.

[0004] Currently, the design of materials based on NO generation mainly includes two types: the first is loading NO or NO donors, but this method has limited loading capacity and is prone to burst release. The other strategy is to immobilize a catalyst on the material surface that can catalyze the generation of NO from donors in the blood. This method can meet the physiological requirements of high-dose and stable-dose NO applications, but many modification methods cannot achieve long-term sustained-release effects, nor can they simultaneously endow the coating with excellent antithrombotic, anti-inflammatory, free radical scavenging, smooth muscle cell abnormal proliferation inhibition, and rapid endothelial regeneration and repair functions.

[0005] In view of this, the present invention is proposed. Summary of the Invention

[0006] The purpose of this invention is to provide a multifunctional coating material, its preparation method, and blood contact medical devices, aiming to enable the prepared coating material to have a long-lasting catalytic effect on the release of endogenous NO, while also meeting the requirements of multifunctionality.

[0007] This invention is implemented as follows:

[0008] In a first aspect, the present invention provides a method for preparing a multifunctional coating material, comprising: placing a substrate in a mixed solution formed by selenocysteine ​​and polyphenolic compounds for pre-crosslinking, and then adding bivalirudin to the pre-crosslinked system to continue the reaction, so as to form an adhesive gel coating on the substrate.

[0009] The substrate with the adhesive gel coating is placed in a selenocysteine ​​solution for reaction.

[0010] In an optional embodiment, the concentration of the polyphenolic compound in the mixed solution is 0.01 mg / mL to 100 mg / mL, and the molar ratio of selenocysteine ​​to the polyphenolic compound is (1-10):(1-10).

[0011] Preferably, the reaction temperature for pre-crosslinking is 10℃-50℃, and the reaction time is 0.5h-48h.

[0012] In an optional embodiment, during the process of adding bivalirudin to the pre-crosslinked system to continue the reaction, the reaction temperature is controlled at 10℃-40℃ and the reaction time is 0.5h-72h.

[0013] Preferably, the concentration of bivalirudin is adjusted to be between 0.01 mg / mL and 100 mg / mL by controlling the amount of bivalirudin added.

[0014] In an optional embodiment, the substrate with the adhesive gel coating is washed with water, kept moist, and then placed in a selenocysteine ​​solution for reaction.

[0015] In an optional embodiment, the pH value of the selenocysteine ​​solution is 8-12, and the reaction temperature in the selenocysteine ​​solution is 0℃-50℃ for 0.5h-72h.

[0016] Preferably, the concentration of the selenocysteine ​​solution is 0.01 mg / mL to 100 mg / mL.

[0017] In an optional embodiment, after the reaction in the selenocysteine ​​solution is complete, the mixture is washed with water multiple times and then dried.

[0018] In an optional embodiment, the polyphenolic compound is selected from at least one of tannic acid, epigallocatechin gallate, proanthocyanidins, theaflavins, anthocyanins, flavonoids, alginic polyphenols, ellagic acid, and ellagitannins.

[0019] In an optional embodiment, the substrate is selected from at least one of metallic materials, inorganic non-metallic materials, and polymeric materials;

[0020] Among them, metallic materials include stainless steel, iron and its alloys, magnesium and its alloys, titanium and its alloys, zinc and its alloys, and cobalt-based alloys;

[0021] Inorganic non-metallic materials include titanium dioxide, titanium oxide, titanium nitride, ceramics, silicon, silicon dioxide, silicon carbide, calcium phosphate, silicon nitride, calcium phosphate, aluminosilicates, bioglass, hydroxyapatite, carbon materials, diamond, and diamond-like carbon.

[0022] Polymer materials include polyester, polyethylene, polyvinyl chloride, polyvinyl alcohol, polypropylene, polycarbonate, carbon copolymer, polyglycolic acid, polymethyl methacrylate, polytetrafluoroethylene, polyoxymethylene, polystyrene, polyvinyl acetate, polylactic acid, polylactic-co-hydroxyacetic acid copolymer, polytrimethylene carbonate, polyhydroxyalkanoates, polybutylene succinate, polyamide, poly(dioxane), epoxy resin, silicone rubber, silicone gel, polyacrylic acid and its derivatives, polyethylene glycol and its derivatives, polyvinyl alcohol, polycaprolactone, and polyurethane.

[0023] Secondly, the present invention provides a multifunctional coating material, which is prepared by any of the preparation methods described in the foregoing embodiments.

[0024] Thirdly, the present invention provides a blood contact medical device, including the multifunctional coating material of the aforementioned embodiments.

[0025] This invention offers the following advantages: First, a substrate is pre-crosslinked in a mixed solution of selenocysteine ​​and polyphenolic compounds to achieve partial pre-adsorption. Then, bivalirudin is added, and under acidic conditions (pH 3-5), an adhesive gel coating is constructed based on the weak interaction between plant polyphenols and bivalirudin. Finally, the gel-coated material is placed in an alkaline solution of selenocysteine ​​(SeCA), and in-situ chemical crosslinking of the gel coating on the material surface is achieved based on a quinone amine chemical reaction. This transforms the gel coating constructed based on weak interactions into a solid coating with a highly quinone amine network structure encapsulating bivalirudin. The conversion coating obtained using this method not only possesses excellent adhesion properties and long-lasting, stable, and controllable NO catalytic release and bivalirudin (BVLD) sustained-release properties, but also endows blood-contact devices with antithrombotic, anti-inflammatory, free radical scavenging, smooth muscle cell abnormal proliferation inhibition, and rapid endothelial regeneration and repair functions. Attached Figure Description

[0026] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.

[0027] Figure 1These are the water contact angle test results for the vascular stent surface coatings of Example 1 and Comparative Example 1;

[0028] Figure 2 This is the macroscopic and microscopic morphology of the surface coating of the medical 316L SS vascular stent in Example 1; in the figure, i represents the macroscopic morphology before and after coating deposition, ii represents the vascular stent with coating deposited after balloon inflating, iii represents the vascular stent with coating deposited before and after balloon inflating, and iv represents electron micrographs of the vascular stent with coating deposited at different magnifications.

[0029] Figure 3 This is the microstructure of the coating after conducting a rabbit in vivo blood circulation experiment in Example 6;

[0030] Figure 4 These are the platelet fluorescence results from Example 3 and Comparative Example 2;

[0031] Figure 5 The microstructure of the surface coating of the medical 316L SS vascular stent in Example 1 and Comparative Example 3 is shown. Detailed Implementation

[0032] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0033] This invention provides a method for preparing a multifunctional coating material, comprising the following steps:

[0034] S1, pre-crosslinking

[0035] The substrate is placed in a mixed solution of selenocysteine ​​and polyphenolic compounds for pre-crosslinking to achieve partial pre-adsorption. In practice, selenocysteine ​​and polyphenolic compounds are dissolved separately in water, then mixed. The substrate can be cleaned before being placed in the mixed solution for pre-crosslinking. Selenocysteine, with amino groups at both ends of its diselenobonds, can chemically react with polyphenolic compounds, achieving coating conversion while providing long-term stable catalysis for the release of endogenous NO.

[0036] In an optional embodiment, the concentration of polyphenolic compounds in the mixed solution is 0.01 mg / mL-100 mg / mL, the molar ratio of selenocysteine ​​to polyphenolic compounds is (1-10):(1-10), the pre-crosslinking reaction temperature is 10℃-50℃, and the reaction time is 0.5 h-48 h. By controlling the amount of selenocysteine ​​and polyphenolic compounds and the reaction conditions, the long-term stable release of NO from the product can be improved.

[0037] Specifically, in the mixed solution, the concentration of polyphenolic compounds can be 0.01 mg / mL, 0.1 mg / mL, 1.0 mg / mL, 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL, etc., and the molar ratio of selenocysteine ​​to polyphenolic compounds can be... The ratios are 1:10, 1:5, 1:1, 2:10, 2:5, 2:1, 3:10, 3:5, 3:1, 4:10, 4:5, 4:1, 5:10, 5:5, 5:1, 6:10, 6:5, 6:1, 7:10, 7:5, 7:1, 8:10, 8:5, 8:1, 9:10, 9:5, 9:1, 10:10, 10:5, 10:1, etc., with a pH value of approximately 3-5. The pre-crosslinking reaction temperature can be 10℃, 20℃, 30℃, 40℃, 50℃, etc., and the reaction time can be 0.5h, 1.0h, 10h, 20h, 30h, 40h, 48h, etc.

[0038] In some embodiments, the polyphenolic compound is selected from at least one of tannic acid (TA), epigallocatechin gallate (EGCG), proanthocyanidins, theaflavins, anthocyanins, flavonoids, brown algae polyphenols, ellagic acid, and ellagitannins, and may be any one or more of the above. Polyphenolic compounds such as tannic acid, epigallocatechin gallate, and brown algae polyphenols found in natural plants generally possess biomedical functions such as anticoagulation, anti-inflammation, antitumor, and antioxidant properties. Furthermore, plant polyphenols have a polyphenolic hydroxyl structure, enabling them to exhibit strong adhesion to various material surfaces.

[0039] The type of substrate is not limited, and a suitable substrate can be selected according to the application of the final product. In some embodiments, the substrate is selected from at least one of metallic materials, inorganic non-metallic materials, and polymeric materials, and can be any one or more of the above.

[0040] Among them, metallic materials include stainless steel, iron and its alloys, magnesium and its alloys, titanium and its alloys, zinc and its alloys, and cobalt-based alloys, and the base material can be any one or more of the above.

[0041] Inorganic non-metallic materials include titanium dioxide, titanium oxide, titanium nitride, ceramics, silicon, silicon dioxide, silicon carbide (SiC), calcium phosphate, silicon nitride (Si3N4), calcium phosphate, aluminosilicates (such as Na2O·Al2O3·SiO2), calcium aluminum series (such as CaO·Al2O3), bioglass (such as SiO2·CaO·Na2O·P2O5), hydroxyapatite, carbon materials (C), diamond and diamond-like carbon. The substrate can be any one or more of the above.

[0042] Polymer materials include polyester (PET), polyethylene (PE), polyvinyl chloride (PVC), polyvinyl alcohol (PVALC), polypropylene (PP), polycarbonate (PC), carbon copolymer (PDC), polyglycolic acid (PGA), polymethyl methacrylate (PMMA), polytetrafluoroethylene (PTFE), polyoxymethylene (POM), polystyrene (PS), polyvinyl acetate (PVA), polylactic acid (PLA), polylactic acid-glycolic acid copolymer (PLGA), polytrimethylene carbonate (PTMC), polyhydroxyalkanoates (PHA), polybutylene succinate (PBS), polyamide (PA), polydioxane (PDS), epoxy resin, silicone rubber, silicone gel, polyacrylic acid (PAA) and its derivatives, polyethylene glycol and its derivatives, polyvinyl alcohol (PVA), polycaprolactone (PCL), and polyurethane (PU). The substrate can be any one or more of the above.

[0043] S2, Introduction of Bivaludin

[0044] Bivalirudin was added to the pre-crosslinked system to continue the reaction. Under acidic conditions, an adhesive gel coating was constructed based on the weak interaction between plant polyphenols and bivalirudin.

[0045] It should be noted that, based on polyphenol-peptide interactions, polyphenolic compounds and bivalirudin can form an adhesive gel coating on the material surface. Bivalirudin is a synthetic short peptide anticoagulant biomolecule that inhibits the activity of thrombin and the series of coagulation reactions it induces by binding to thrombin. The binding process of bivalirudin to thrombin is reversible and transient, and its inhibition of thrombin does not require cofactors such as AT-III.

[0046] Specifically, the material was purchased from Chengdu Kaijie Biomedical Technology Development Co., Ltd.

[0047] In some embodiments, during the process of adding bivalirudin to the pre-crosslinked system and continuing the reaction, the reaction temperature is controlled at 10℃-40℃ and the reaction time is 0.5h-72h; the concentration of bivalirudin is adjusted to 0.01mg / mL-100mg / mL by controlling the amount of bivalirudin added. The amount of bivalirudin introduced can be increased by further controlling the reaction parameters.

[0048] Specifically, the concentration of bivalirudin can be 0.01 mg / mL, 0.1 mg / mL, 1.0 mg / mL, 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL, etc., the reaction temperature can be 10℃, 20℃, 30℃, 40℃, etc., and the reaction time can be 0.5h, 1.0h, 10h, 20h, 30h, 40h, 50h, 60h, 70h, 72h, etc.

[0049] In some embodiments, after washing the substrate with the adhesive gel coating with water, the surface is kept moist and then placed in a selenocysteine ​​solution to react in reaction S3. Specifically, the water washing can be performed by rinsing with ultrapure water 3-4 times.

[0050] S3, quinone amine chemical crosslinking

[0051] The substrate with the adhesive gel coating is placed in a selenocysteine ​​solution for reaction. In the alkaline selenocysteine ​​(SeCA) solution, in-situ chemical crosslinking of the gel coating on the material surface is achieved based on the quinone amine chemical reaction, transforming the gel coating based on weak interactions into a solid coating with a highly quinone amine network structure that encapsulates bivalirudin.

[0052] In some embodiments, the pH value of the selenocysteine ​​solution is 8-12, and the reaction temperature in the selenocysteine ​​solution is 0℃-50℃ for 0.5h-72h. By controlling the reaction conditions, the prepared coating has better stability and achieves a long-term stable sustained release effect.

[0053] Specifically, the pH value of the selenocysteine ​​solution can be 8, 9, 10, 11, 12, etc., the reaction temperature in the selenocysteine ​​solution can be 0℃, 10℃, 20℃, 30℃, 40℃, 50℃, etc., and the reaction time can be 0.5h, 1.0h, 10.0h, 20.0h, 30.0h, 40.0h, 50.0h, 60.0h, 70.0h, 72.0h, etc.

[0054] Specifically, the selenocysteine ​​solution is obtained by mixing and dissolving selenocysteine ​​in water. The concentration of the selenocysteine ​​solution is 0.01 mg / mL to 100 mg / mL, such as 0.01 mg / mL, 0.1 mg / mL, 1.0 mg / mL, 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL, etc.

[0055] In some embodiments, after the reaction in the selenocysteine ​​solution is completed, the product is washed with water multiple times and then dried. The water washing can be done with ultrapure water 3-4 times, and the drying can be carried out under a nitrogen atmosphere.

[0056] This invention provides a multifunctional coating material prepared by the above-described method. This coating material has the advantages of strong adhesion and good chemical stability, enabling successful loading of bivalirudin. It can catalyze the release of endogenous NO for a long time, while endowing blood contact medical devices with excellent antithrombotic, anti-inflammatory, free radical scavenging, smooth muscle cell abnormal proliferation inhibition and rapid endothelial regeneration and repair functions.

[0057] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0058] It should be noted that the raw materials used in the following examples or comparative examples are all commercially available, such as selenocysteine ​​purchased from Aladdin, brown algae polyphenol PTA purchased from Xi'an Baichuan Biotechnology Co., Ltd., and bivalirudin purchased from Chengdu Kaijie Biomedical Technology Development Co., Ltd.

[0059] Example 1

[0060] This embodiment provides a method for preparing a multifunctional coating material, using medical 316L SS vascular stent as the substrate material for coating preparation, and includes the following steps:

[0061] (1) The surface of the 316L SS vascular stent was cleaned and dried;

[0062] (2) Selenocysteine ​​and brown algae polyphenol PTA were dissolved in ultrapure water at a molar ratio of 3:1 to prepare a mixed solution, wherein the final concentration of PTA was 0.35 mg / mL. The vascular stent was placed in the solution and pre-crosslinked at 25°C for 24 h.

[0063] (3) Add bivalirudin to the acidic mixed solution described in step (2) to make the concentration of bivalirudin 2 mg / mL, and react at 25°C for 24 h. After the reaction is completed, an adhesive gel coating is obtained.

[0064] (4) Remove the support and rinse the surface with ultrapure water 3-4 times to keep the sample surface moist.

[0065] (5) Prepare a 2 mg / mL selenocysteine ​​solution and adjust the pH of the solution to about 8.5 (add sodium hydroxide solution to adjust the pH, the same below). Place the sample with the adhesive coating obtained in step (4) into it and react at 25°C for 24 h. Then wash the surface with ultrapure water 3-4 times and dry it under air conditions to obtain (denoted as PTA@BVLD@SeCA).

[0066] Example 2

[0067] This embodiment provides a method for preparing a multifunctional coating material, using a cobalt-chromium alloy vascular stent as the substrate material for coating preparation, and includes the following steps:

[0068] (1) Clean and dry the cobalt-chromium alloy vascular stent;

[0069] (2) Selenocysteine ​​and proanthocyanidins were dissolved in ultrapure water at a molar ratio of 3:1 to prepare a mixed solution, wherein the final concentration of proanthocyanidins was 0.5 mg / mL. The vascular stent was placed in the solution and pre-crosslinked at 25°C for 24 h.

[0070] (3) Add bivalirudin to the acidic mixed solution described in step (2) to make the concentration of bivalirudin 1 mg / mL, and react at 25°C for 24 h. After the reaction is completed, an adhesive gel coating is obtained.

[0071] (4) Wash the sample obtained in step (3) with ultrapure water 3-4 times to keep the sample surface moist.

[0072] (5) Prepare a 2 mg / mL selenocysteine ​​solution, adjust the pH of the solution to about 8.5, place the sample with the adhesive gel coating obtained in step (4) into it, react at 25°C for 24 h, then wash the surface with ultrapure water 3-4 times, and dry it under air conditions to obtain the product.

[0073] Example 3

[0074] This embodiment provides a method for preparing a multifunctional coating material, using silicone rubber sheet as the substrate material for coating preparation, and includes the following steps:

[0075] (1) Clean and dry the silicone rubber sheet;

[0076] (2) Selenocystamine and tannic acid were dissolved in ultrapure water at a molar ratio of 2:1 to prepare a mixed solution, wherein the final concentration of tannic acid was 1 mg / mL. The substrate was placed in the solution and pre-crosslinked at 25°C for 24 h.

[0077] (3) Add bivalirudin to the acidic mixed solution described in step (2) to make the concentration of bivalirudin 3 mg / mL, and react at 37°C for 24 h. After the reaction is completed, an adhesive gel coating is obtained.

[0078] (4) Wash the sample obtained in step (3) with ultrapure water 3-4 times to keep the sample surface moist.

[0079] (5) Prepare a 2 mg / mL selenocysteine ​​solution, adjust the pH of the solution to about 8.5, place the sample with the adhesive hydrogel coating obtained in step (4) into it, react at 37°C for 24 h, then wash the surface with ultrapure water 3-4 times, and dry it under air conditions to obtain (denoted as TA@BVLD@SeCA).

[0080] Example 4

[0081] This embodiment provides a method for preparing a multifunctional coating material, using a cobalt-chromium alloy vascular stent as the substrate material for coating preparation, and includes the following steps:

[0082] (1) Clean and dry the cobalt-chromium alloy vascular stent;

[0083] (2) Selenocystamine, brown algae polyphenol PTA, and tannic acid TA were dissolved in ultrapure water at a molar ratio of 4:1:1 to prepare a mixed solution, wherein the final concentration of selenocystamine was 1 mg / mL. The vascular stent was placed in the solution and pre-crosslinked at 25°C for 24 h.

[0084] (3) Add bivalirudin to the acidic mixed solution described in step (2) to make the concentration of bivalirudin 4 mg / mL, and react at 25°C for 24 h. After the reaction is completed, an adhesive gel coating is obtained.

[0085] (4) Wash the sample obtained in step (3) with ultrapure water 3-4 times to keep the sample surface moist.

[0086] (5) Prepare a 2 mg / mL selenocysteine ​​solution, adjust the pH of the solution to about 8.5, place the sample with the adhesive hydrogel coating obtained in step (4) into it, react at 25°C for 24 h, then wash the surface with ultrapure water 3-4 times, and dry it under air conditions to obtain the product.

[0087] Example 5

[0088] This embodiment provides a method for preparing a multifunctional coating material, using polylactic acid scaffold as the substrate material for coating preparation, and includes the following steps:

[0089] (1) Clean and dry the polylactic acid scaffold;

[0090] (2) Selenocystamine, brown algae polyphenol PTA, and epigallocatechin gallate (EGCG) were dissolved in ultrapure water at a molar ratio of 3:1:1 to prepare a mixed solution, wherein the final concentration of selenocystamine was 1 mg / mL. The vascular stent was placed in the solution and pre-crosslinked at 25°C for 12 h.

[0091] (3) Add bivalirudin to the acidic mixed solution described in step (2) to make the concentration of bivalirudin 3 mg / mL, and react at 37°C for 12 h. After the reaction is completed, an adhesive gel coating is obtained.

[0092] (4) Wash the sample obtained in step (3) with ultrapure water 3-4 times to keep the sample surface moist.

[0093] (5) Prepare a 2 mg / mL selenocysteine ​​solution, adjust the pH of the solution to about 8.5, place the sample with the adhesive hydrogel coating obtained in step (4) into it, react at 37°C for 24 h, then wash the surface with ultrapure water 3-4 times, and dry it under air conditions to obtain the product.

[0094] Example 6

[0095] The only difference from Example 1 is that the substrate material used is medical 316L SS sheet.

[0096] Comparative Example 1

[0097] This comparative example provides a method for preparing a multifunctional coating material, using medical 316L SS vascular stent as the substrate material for coating preparation, including the following steps:

[0098] (1) The medical 316L SS vascular stent was cleaned and dried;

[0099] (2) Selenocysteine ​​and brown algae polyphenol PTA were dissolved in ultrapure water at a molar ratio of 3:1 to prepare a mixed solution, wherein the final concentration of PTA was 0.35 mg / mL. The vascular stent was placed in the solution and pre-crosslinked at 25°C for 24 h.

[0100] (3) Add bivalirudin to the acidic mixed solution described in step (2) to make the concentration of bivalirudin 2 mg / mL, and react at 25°C for 24 h. After the reaction is completed, an adhesive gel coating is obtained.

[0101] (4) Remove the support, wash the surface with ultrapure water 3-4 times, and then dry it in the air to obtain (denoted as PTA@BVLD).

[0102] Note: The only difference between Comparative Example 1 and Example 1 is that step (5) is omitted, and drying is performed directly after step (4).

[0103] Comparative Example 2

[0104] This comparative example provides a method for preparing a functional coating material, which adopts a traditional method for preparing polyphenol coatings, and the steps are as follows:

[0105] (1) Clean and dry the surface of the silicone rubber sheet;

[0106] (2) The silicone rubber sheet was placed in a dopamine solution with a final concentration of 1 mg / mL and a TrisBase solution (pH 8.5) as the solvent. After reacting at 25°C for 24 h, the sheet was removed, washed with water, and dried to obtain (denoted as pDA).

[0107] This comparative example uses only a single phenolic substance for modification, resulting in a limited function. Furthermore, it requires secondary grafting of functional molecules to achieve a function similar to that of the embodiments of this invention.

[0108] Comparative Example 3

[0109] The only difference from Example 1 is that: no pre-crosslinking is performed, and selenocysteine, plant polyphenols and bivalirudin are directly mixed to obtain a mixed solution for the reaction in step (3) (referred to as no pre-crosslinking).

[0110] Experimental Example 1

[0111] (1) The water contact angle of the vascular stent surface coatings in Example 1 and Comparative Example 1 was tested, and the test results are as follows: Figure 1 As shown, the water contact angle of PTA@BVLD@SeCA prepared in Example 1 is significantly larger than that of PTA@BVLD prepared in Comparative Example 1.

[0112] (2) The microstructure of the surface coating of the medical 316L SS vascular stent prepared in Example 1 was tested, and the results are as follows: Figure 2 As shown, the coating maintains good adhesion to the support surface and is deposited uniformly without obvious cracking, proving that the coating can fully adapt to the deformation of the support when it is stretched and compressed.

[0113] Experimental Example 2

[0114] The material prepared in Example 6 was subjected to an in vivo blood circulation experiment in rabbits. The microstructure of the coating after the experiment is shown in the figure below. Figure 3 As shown.

[0115] Experimental Methods: 1) Healthy New Zealand white rabbits were selected and managed according to standard laboratory animal husbandry methods. A 30 mg / mL pentobarbital solution was prepared using physiological saline as an anesthetic (1 mL / kg per rabbit), and filtered. 2) The anesthetic was injected into the blood vessels in the rabbit's ear. After the rabbit was fully anesthetized, the hair on its neck was completely shaved. The skin of the neck was incised with a scalpel to expose both the jugular vein and carotid artery. 3) One end of a catheter with the sample was carefully inserted into the exposed carotid artery and then secured with sutures. The other end of the catheter was inserted into the exposed jugular vein, ensuring no air entered the blood vessel. The blood in the catheter was observed for 2 hours, including color, temperature, and flow. Subsequently, the catheter was removed and rinsed with physiological saline. The sample was fixed with 2.5% glutaraldehyde for 12 hours for dehydration and de-alcoholization. Finally, the sample surface was observed using a scanning electron microscope.

[0116] from Figure 3 It can be seen that the surface of the 316L SS group has a large number of blood cells (red blood cells, platelets, etc.) and reticular fibrin structures forming thrombi, while the surface of the coating of the present invention does not show obvious thrombus formation, indicating that the coating prepared by the present invention has excellent antithrombotic properties.

[0117] Experimental Example 3

[0118] Platelet fluorescence experiments were conducted using the materials obtained in Example 3 and Comparative Example 2, and the results are as follows: Figure 4 As shown.

[0119] Experimental Methods: A static platelet adhesion assay was used to compare the traditional dopamine coating with that of Example 3. First, whole blood was collected from healthy New Zealand white rabbits using a vacuum tube containing sodium citrate as an anticoagulant. Platelet-rich plasma (PRP) was collected by centrifugation at 1500 rpm for 15 min. 200 μL of fresh PRP was added to both coating surfaces and incubated at 37°C for 30 min. Unattached platelets were washed with physiological saline, fixed in 2.5% glutaraldehyde solution for 12 h, stained with rhodamine B, and the platelet count was determined using a fluorescence inverted microscope.

[0120] The result is as follows Figure 4 As shown, the left side represents the traditional coating, and the right side represents the coating prepared by the present invention. It can be seen from the figure that the number of platelets adhering to the coating prepared by the present invention is significantly inhibited, indicating that the coating prepared by the present invention has excellent anticoagulant properties.

[0121] Test Example 4

[0122] The surface microstructure of the materials obtained in Example 1 and Comparative Example 3 was characterized, and the results are as follows: Figure 5As shown in the figure, the left side is the uncrosslinked coating and the right side is the coating prepared by the present invention. It can be seen from the figure that the uniformity of coating deposition on the stent surface is significantly improved after precrosslinking, indicating that the coating prepared by the present invention has good adhesion to the stent surface and uniform deposition.

[0123] In summary, the embodiments of the present invention provide a multifunctional coating material, its preparation method, and a blood contact medical device. The material prepared by surface modification of the substrate with selenocysteine, polyphenolic compounds, and bivalirudin has the following advantages:

[0124] (1) The multifunctional coating prepared by the method of this invention, which has catalytic release of nitric oxide (NO) and bivalirudin elution (BVLD), has a wide range of applications. Due to the adhesive properties of polyhydroxy phenolic compounds, it is suitable for almost all material surfaces.

[0125] (2) Traditional polyphenol coatings are modified with only a single phenolic substance, resulting in a single function. However, the coating prepared by this method not only realizes the function of polyphenol compounds, but also introduces the anticoagulant peptide bivalirudin through weak interaction, giving it excellent anticoagulant properties. Furthermore, the plant polyphenols and selenocysteine ​​undergo chemical cross-linking, achieving the long-term stable release of endogenous NO.

[0126] (3) This multifunctional coating successfully loaded bivalirudin without introducing polymers that could cause local inflammation and thrombosis. Furthermore, all components used in the coating are active ingredients, avoiding the use of polymers while achieving synergistic healing of the lesions through the interaction of the components.

[0127] The above are merely preferred embodiments of the present invention and are not intended to limit the present invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A method for preparing a multifunctional coating material, characterized in that, include: The substrate was pre-crosslinked in a mixed solution of selenocysteine ​​and polyphenolic compounds, and then bivalirudin was added to the pre-crosslinked system and the reaction continued under acidic conditions to form an adhesive gel coating on the substrate. After washing the substrate with the adhesive gel coating, the surface is kept moist and then placed in a selenocysteine ​​solution for reaction; the pH value of the selenocysteine ​​solution is 8-12.

2. The preparation method according to claim 1, characterized in that, In the mixed solution, the concentration of the polyphenolic compound is 0.01 mg / mL to 100 mg / mL, and the molar ratio of the selenocysteine ​​to the polyphenolic compound is (1-10):(1-10).

3. The preparation method according to claim 1, characterized in that, The reaction temperature for pre-crosslinking is 10℃-50℃, and the reaction time is 0.5h-48h.

4. The preparation method according to claim 1, characterized in that, During the reaction of adding bivalirudin to the pre-crosslinked system, the reaction temperature was controlled at 10℃-40℃ and the reaction time was 0.5h-72h.

5. The preparation method according to claim 4, characterized in that, By adjusting the amount of bivalirudin added, the concentration of bivalirudin can be adjusted to be between 0.01 mg / mL and 100 mg / mL.

6. The preparation method according to claim 1, characterized in that, The reaction in the selenocysteine ​​solution was carried out at a temperature of 0℃-50℃ for 0.5h-72h.

7. The preparation method according to claim 6, characterized in that, The concentration of the selenocysteine ​​solution is 0.01 mg / mL to 100 mg / mL.

8. The preparation method according to claim 6, characterized in that, After the reaction in the selenocysteine ​​solution is complete, the mixture is washed with water multiple times and then dried.

9. The preparation method according to claim 1, characterized in that, The polyphenolic compounds are selected from at least one of tannic acid, epigallocatechin gallate, proanthocyanidins, theaflavins, anthocyanins, alginic acid, ellagic acid, and ellagitannins.

10. The preparation method according to claim 1, characterized in that, The substrate is selected from at least one of metallic materials, inorganic non-metallic materials, and polymeric materials; The metallic materials include iron and its alloys, magnesium and its alloys, titanium and its alloys, zinc and its alloys, and cobalt-based alloys; The inorganic non-metallic materials include titanium oxide, titanium nitride, silicon, silicon dioxide, silicon carbide, calcium phosphate, silicon nitride, aluminosilicate, bioglass, hydroxyapatite, diamond, and diamond-like carbon. The polymeric materials include polyester, polyethylene, polyvinyl chloride, polyvinyl alcohol, polypropylene, polycarbonate, polyglycolic acid, polymethyl methacrylate, polytetrafluoroethylene, polyoxymethylene, polystyrene, polyvinyl acetate, polylactic acid, polylactic-glycolic acid copolymer, polytrimethylene carbonate, polyhydroxyalkanoates, polybutylene succinate, polyamide, polydioxane, epoxy resin, silicone rubber, silicone gel, polyacrylic acid and its derivatives, polyethylene glycol and its derivatives, polycaprolactone, and polyurethane.

11. A multifunctional coating material, characterized in that, It is prepared by the preparation method according to any one of claims 1-10.

12. A blood contact medical device, characterized in that, Includes the multifunctional coating material as described in claim 11.

Citation Information

Patent Citations

  • Preparation method of anticoagulant material with function of inducing and catalyzing release of endogenous NO

    CN104208761A